Monoclonal Antibody to Interferon Alpha/Beta Receptor 1 (IFNa/bR1)
| Code | Size | Price |
|---|
| MAB425Hu22-20ul | 20ul | £89.00 |
Quantity:
| MAB425Hu22-100ul | 100ul | £166.00 |
Quantity:
| MAB425Hu22-200ul | 200ul | £224.00 |
Quantity:
| MAB425Hu22-1ml | 1ml | £515.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Clonality: Monoclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
IFNAR1; AVP; IFN-alpha-REC; IFNAR; IFNBR; IFRC; Interferon-Alpha, Beta And Omega Receptor Alpha Chain; Cytokine receptor family 2 member 1
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Interferon Alpha/Beta Receptor 1
Potency (Clone Number):
C3
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL
Immunohistochemistry: 5-20ug/mL
Immunocytochemistry: 5-20ug/mL
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL
Immunocytochemistry: 5-20ug/mL
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Interferon Alpha/Beta Receptor 1 (IFNa/bR1) | RPB425Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||